{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:50:55Z","timestamp":1790974255854,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008628","name":"Department of Clinical Medicine, Aarhus University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008628","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Eva and Henry Fr\u00e6nkel\u2019s Memorial Foundation"},{"name":"Raimond and Dagmar Ringg\u00e5rd-Bohn\u2019s Foundation"},{"name":"Butcher Max W\u00f8rzner and wife W\u00f8rzner\u2019s Memorial Grant"},{"name":"Master Carpenter J\u00f8rgen Holm and wife Elisa f. Hansen\u2019s Memorial Grant"},{"name":"A.P. M\u00f8ller Foundation for the Advancement of Medical Sciences"},{"name":"Dagmar Marshall\u2019s Foundation"},{"name":"Farmer of \"\u00d8lufg\u00e5rd\" Peder Nielsen Kristensens Memorial Foundation"},{"name":"the Karen Elise Jensen Foundation"},{"name":"Merchant Einar Willumsen\u2019s Memorial Foundation"},{"name":"the Danish Lymphoma Group"},{"name":"a donation from Peter and Alice Madsen"},{"name":"Knud and Edith Eriksen\u2019s Memorial Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81693-4","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T14:41:14Z","timestamp":1733150474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Differential tumor protein expression at follicular lymphoma diagnosis reveals dysregulation of key molecular pathways associated with histological transformation"],"prefix":"10.1038","volume":"14","author":[{"given":"Marie Hairing","family":"Enemark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Wolter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Engelbrecht","family":"Hybel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja Dam","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma Frasez","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linnea Meier","family":"Hindkaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina Lystlund","family":"Lauridsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Lindhardt","family":"Plesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hamilton-Dutoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Ludvigsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"issue":"Suppl 1(Suppl 1","key":"81693_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/hon.3138","volume":"41","author":"JW Friedberg","year":"2023","unstructured":"Friedberg, J. W. Update on follicular lymphoma. Hematol. Oncol. 41 (Suppl 1(Suppl 1), 43\u201347 (2023).","journal-title":"Hematol. Oncol."},{"issue":"20","key":"81693_CR2","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127 (20), 2375\u20132390 (2016).","journal-title":"Blood"},{"issue":"1","key":"81693_CR3","doi-asserted-by":"publisher","first-page":"6772","DOI":"10.1038\/s41467-022-34408-0","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk. Nat. Commun. 13 (1), 6772 (2022).","journal-title":"Nat. Commun."},{"issue":"12","key":"81693_CR4","doi-asserted-by":"publisher","first-page":"e1002197","DOI":"10.1371\/journal.pmed.1002197","volume":"13","author":"R Kridel","year":"2016","unstructured":"Kridel, R. et al. Histological Transformation and Progression in Follicular Lymphoma: a clonal evolution study. PLoS Med. 13 (12), e1002197 (2016).","journal-title":"PLoS Med."},{"issue":"7","key":"81693_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood-2015-01-621375","volume":"126","author":"ND Wagner-Johnston","year":"2015","unstructured":"Wagner-Johnston, N. D. et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood 126 (7), 851\u2013857 (2015).","journal-title":"Blood"},{"issue":"22","key":"81693_CR6","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1200\/JCO.2015.65.7163","volume":"34","author":"C Sarkozy","year":"2016","unstructured":"Sarkozy, C. et al. Risk factors and outcomes for patients with follicular Lymphoma who had histologic Transformation after response to First-Line Immunochemotherapy in the PRIMA Trial. J. Clin. Oncol. 34 (22), 2575\u20132582 (2016).","journal-title":"J. Clin. Oncol."},{"key":"81693_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2147\/OTT.S289337","volume":"14","author":"M Beck Enemark","year":"2021","unstructured":"Beck Enemark, M. et al. PD-1 expression in Pre-treatment Follicular Lymphoma predicts the risk of subsequent high-Grade Transformation. Onco Targets Ther. 14, 481\u2013489 (2021).","journal-title":"Onco Targets Ther."},{"issue":"1","key":"81693_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bjh.14201","volume":"175","author":"YN Blaker","year":"2016","unstructured":"Blaker, Y. N. et al. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the Rituximab era. Br. J. Haematol. 175 (1), 102\u2013114 (2016).","journal-title":"Br. J. Haematol."},{"issue":"21","key":"81693_CR9","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave, S. S. et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl. J. Med. 351 (21), 2159\u20132169 (2004).","journal-title":"N Engl. J. Med."},{"issue":"11","key":"81693_CR10","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","volume":"20","author":"JP Smeltzer","year":"2014","unstructured":"Smeltzer, J. P. et al. Pattern of CD14\u2009+\u2009follicular dendritic cells and PD1\u2009+\u2009T cells independently predicts time to transformation in follicular lymphoma. Clin. Cancer Res. 20 (11), 2862\u20132872 (2014).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"81693_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","volume":"16","author":"BE Wahlin","year":"2010","unstructured":"Wahlin, B. E. et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1\u2013positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin. Cancer Res. 16 (2), 637\u2013650 (2010).","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"81693_CR12","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","volume":"45","author":"MH Andersen","year":"2023","unstructured":"Andersen, M. H. Tumor microenvironment antigens. Semin Immunopathol. 45 (2), 253\u2013264 (2023).","journal-title":"Semin Immunopathol."},{"issue":"24","key":"81693_CR13","doi-asserted-by":"publisher","first-page":"7418","DOI":"10.1182\/bloodadvances.2023011299","volume":"7","author":"MBH Enemark","year":"2023","unstructured":"Enemark, M. B. H. et al. Proteomics identifies apoptotic markers as predictors of histological transformation in patients with follicular lymphoma. Blood Adv. 7 (24), 7418\u20137432 (2023).","journal-title":"Blood Adv."},{"issue":"6","key":"81693_CR14","doi-asserted-by":"publisher","first-page":"e0157999","DOI":"10.1371\/journal.pone.0157999","volume":"11","author":"B Arboe","year":"2016","unstructured":"Arboe, B. et al. The Danish National Lymphoma Registry: Coverage and Data Quality. PLoS One. 11 (6), e0157999 (2016).","journal-title":"PLoS One"},{"key":"81693_CR15","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2147\/CLEP.S99470","volume":"8","author":"B Arboe","year":"2016","unstructured":"Arboe, B. et al. Danish National Lymphoma Registry. Clin. Epidemiol. 8, 577\u2013581 (2016).","journal-title":"Clin. Epidemiol."},{"key":"81693_CR16","doi-asserted-by":"crossref","unstructured":"Enemark, M. B. et al. Tumor-tissue expression of the Hyaluronic acid receptor RHAMM predicts histological Transformation in Follicular Lymphoma patients. Cancers (Basel) ;14(5). (2022).","DOI":"10.3390\/cancers14051316"},{"issue":"4","key":"81693_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-019-0197-5","volume":"9","author":"C Madsen","year":"2019","unstructured":"Madsen, C. et al. High intratumoral expression of vimentin predicts histological transformation in patients with follicular lymphoma. Blood Cancer J. 9 (4), 35 (2019).","journal-title":"Blood Cancer J."},{"issue":"11","key":"81693_CR18","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1080\/10428194.2020.1779254","volume":"61","author":"C Madsen","year":"2020","unstructured":"Madsen, C. et al. Real world data on histological transformation in patients with follicular lymphoma: incidence, clinico-pathological risk factors and outcome in a nationwide Danish cohort. Leuk. Lymphoma. 61 (11), 2584\u20132594 (2020).","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"81693_CR19","doi-asserted-by":"publisher","first-page":"e0233449","DOI":"10.1371\/journal.pone.0233449","volume":"15","author":"I Monrad","year":"2020","unstructured":"Monrad, I. et al. Glycolytic biomarkers predict transformation in patients with follicular lymphoma. PLoS One. 15 (5), e0233449 (2020).","journal-title":"PLoS One"},{"key":"81693_CR20","doi-asserted-by":"crossref","unstructured":"Enemark, M. B. H. et al. IDO1 protein is expressed in Diagnostic biopsies from both follicular and transformed follicular patients. Int. J. Mol. Sci. ;24(8). (2023).","DOI":"10.3390\/ijms24087314"},{"issue":"4","key":"81693_CR21","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.hoc.2020.02.010","volume":"34","author":"EA Kumar","year":"2020","unstructured":"Kumar, E. A., Okosun, J. & Fitzgibbon, J. The Biological basis of histologic Transformation. Hematol. Oncol. Clin. North. Am. 34 (4), 771\u2013784 (2020).","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"81693_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cca.2012.12.012","volume":"417","author":"C Guo","year":"2013","unstructured":"Guo, C., Liu, S., Wang, J., Sun, M. Z. & Greenaway, F. T. ACTB in cancer. Clin. Chim. Acta. 417, 39\u201344 (2013).","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"81693_CR23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/elps.200800508","volume":"30","author":"M Weinkauf","year":"2009","unstructured":"Weinkauf, M. et al. 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma. Electrophoresis 30 (6), 974\u2013986 (2009).","journal-title":"Electrophoresis"},{"issue":"1","key":"81693_CR24","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.1080\/21655979.2021.1973220","volume":"12","author":"Y Gu","year":"2021","unstructured":"Gu, Y. et al. A pan-cancer analysis of the prognostic and immunological role of \u03b2-actin (ACTB) in human cancers. Bioengineered 12 (1), 6166\u20136185 (2021).","journal-title":"Bioengineered"},{"issue":"21","key":"81693_CR25","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1091\/mbc.e11-06-0582","volume":"22","author":"TM Bunnell","year":"2011","unstructured":"Bunnell, T. M., Burbach, B. J., Shimizu, Y. & Ervasti, J. M. \u03b2-Actin specifically controls cell growth, migration, and the G-actin pool. Mol. Biol. Cell. 22 (21), 4047\u20134058 (2011).","journal-title":"Mol. Biol. Cell."},{"issue":"3","key":"81693_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4161\/bioa.20975","volume":"2","author":"M Desouza","year":"2012","unstructured":"Desouza, M., Gunning, P. W. & Stehn, J. R. The actin cytoskeleton as a sensor and mediator of apoptosis. Bioarchitecture 2 (3), 75\u201387 (2012).","journal-title":"Bioarchitecture"},{"issue":"Pt 5","key":"81693_CR27","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1242\/jcs.090514","volume":"125","author":"L Happo","year":"2012","unstructured":"Happo, L., Strasser, A. & Cory, S. BH3-only proteins in apoptosis at a glance. J. Cell. Sci. 125 (Pt 5), 1081\u20131087 (2012).","journal-title":"J. Cell. Sci."},{"key":"81693_CR28","doi-asserted-by":"publisher","first-page":"953203","DOI":"10.1155\/2014\/953203","volume":"2014","author":"M Gryko","year":"2014","unstructured":"Gryko, M. et al. The expression of Bcl-2 and BID in gastric cancer cells. J. Immunol. Res. 2014, 953203 (2014).","journal-title":"J. Immunol. Res."},{"issue":"6","key":"81693_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1515\/BC.2004.053","volume":"385","author":"C Rupnarain","year":"2004","unstructured":"Rupnarain, C., Dlamini, Z., Naicker, S. & Bhoola, K. Colon cancer: genomics and apoptotic events. Biol. Chem. 385 (6), 449\u2013464 (2004).","journal-title":"Biol. Chem."},{"issue":"3","key":"81693_CR30","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/carcin\/bgh345","volume":"26","author":"Q Gu","year":"2005","unstructured":"Gu, Q. et al. Activation of the caspase-8\/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer. Carcinogenesis 26 (3), 541\u2013546 (2005).","journal-title":"Carcinogenesis"},{"issue":"13","key":"81693_CR31","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.1158\/1078-0432.CCR-07-5160","volume":"14","author":"FA Sinicrope","year":"2008","unstructured":"Sinicrope, F. A. et al. Proapoptotic bad and bid protein expression predict survival in stages II and III colon cancers. Clin. Cancer Res. 14 (13), 4128\u20134133 (2008).","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"81693_CR32","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/s41388-018-0123-5","volume":"37","author":"J Debernardi","year":"2018","unstructured":"Debernardi, J., Hollville, E., Lipinski, M., Wiels, J. & Robert, A. Differential role of FL-BID and t-BID during verotoxin-1-induced apoptosis in Burkitt\u2019s lymphoma cells. Oncogene 37 (18), 2410\u20132421 (2018).","journal-title":"Oncogene"},{"issue":"1","key":"81693_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","volume":"141","author":"K Kessenbrock","year":"2010","unstructured":"Kessenbrock, K., Plaks, V. & Werb, Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141 (1), 52\u201367 (2010).","journal-title":"Cell"},{"key":"81693_CR34","doi-asserted-by":"crossref","unstructured":"Niland, S., Riscanevo, A. X. & Eble, J. A. Matrix metalloproteinases shape the Tumor Microenvironment in Cancer Progression. Int. J. Mol. Sci. ;23(1). (2021).","DOI":"10.3390\/ijms23010146"},{"key":"81693_CR35","doi-asserted-by":"crossref","unstructured":"Sakata, K. et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-hodgkin lymphoma. Cancer 100 (2), 356\u2013365 (2004).","DOI":"10.1002\/cncr.11905"},{"issue":"2","key":"81693_CR36","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/j.1368-5031.2004.0023.x","volume":"58","author":"B Hazar","year":"2004","unstructured":"Hazar, B. et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin\u2019s and Non-hodgkin\u2019s lymphoma. Int. J. Clin. Pract. 58 (2), 139\u2013143 (2004).","journal-title":"Int. J. Clin. Pract."},{"issue":"5\u20136","key":"81693_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3109\/10428190009113379","volume":"39","author":"AE Kossakowska","year":"2000","unstructured":"Kossakowska, A. E., Urbanski, S. J. & Janowska-Wieczorek, A. Matrix metalloproteinases and their tissue inhibitors - expression, role and regulation in human malignant non-hodgkin\u2019s lymphomas. Leuk. Lymphoma. 39 (5\u20136), 485\u2013493 (2000).","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"81693_CR38","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/leu.2011.248","volume":"26","author":"S Fruchon","year":"2012","unstructured":"Fruchon, S. et al. Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. Leukemia 26 (4), 795\u2013805 (2012).","journal-title":"Leukemia"},{"key":"81693_CR39","doi-asserted-by":"publisher","first-page":"5369104","DOI":"10.1155\/2022\/5369104","volume":"2022","author":"Q Zhang","year":"2022","unstructured":"Zhang, Q. & Wang, M. Identification of hub genes and key pathways Associated with Follicular Lymphoma. Contrast Media Mol. Imaging. 2022, 5369104 (2022).","journal-title":"Contrast Media Mol. Imaging"},{"issue":"1","key":"81693_CR40","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12967-021-03078-9","volume":"19","author":"Y Zhou","year":"2021","unstructured":"Zhou, Y. et al. Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy. J. Transl Med. 19 (1), 399 (2021).","journal-title":"J. Transl Med."},{"issue":"2","key":"81693_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1385\/IR:31:2:119","volume":"31","author":"CJ Del Nagro","year":"2005","unstructured":"Del Nagro, C. J. et al. CD19 function in central and peripheral B-cell development. Immunol. Res. 31 (2), 119\u2013131 (2005).","journal-title":"Immunol. Res."},{"issue":"1","key":"81693_CR42","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang, K., Wei, G. & Liu, D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp. Hematol. Oncol. 1 (1), 36 (2012).","journal-title":"Exp. Hematol. Oncol."},{"issue":"2","key":"81693_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1042\/BST20160478","volume":"45","author":"F Vences-Catal\u00e1n","year":"2017","unstructured":"Vences-Catal\u00e1n, F. et al. CD81 as a tumor target. Biochem. Soc. Trans. 45 (2), 531\u2013535 (2017).","journal-title":"Biochem. Soc. Trans."},{"issue":"1","key":"81693_CR44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1053\/j.gastro.2008.03.024","volume":"135","author":"A Mazzocca","year":"2008","unstructured":"Mazzocca, A., Liotta, F. & Carloni, V. Tetraspanin CD81-regulated cell motility plays a critical role in intrahepatic metastasis of hepatocellular carcinoma. Gastroenterology 135 (1), 244\u2013256e241 (2008).","journal-title":"Gastroenterology"},{"issue":"2","key":"81693_CR45","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s13402-012-0119-z","volume":"36","author":"TH Yoo","year":"2013","unstructured":"Yoo, T. H., Ryu, B. K., Lee, M. G. & Chi, S. G. CD81 is a candidate tumor suppressor gene in human gastric cancer. Cell. Oncol. (Dordr). 36 (2), 141\u2013153 (2013).","journal-title":"Cell. Oncol. (Dordr)"},{"issue":"4","key":"81693_CR46","doi-asserted-by":"publisher","first-page":"e0125405","DOI":"10.1371\/journal.pone.0125405","volume":"10","author":"MS Lee","year":"2015","unstructured":"Lee, M. S. et al. Prognostic significance of CREB-Binding protein and CD81 expression in primary high Grade Non-muscle invasive bladder Cancer: identification of novel biomarkers for bladder Cancer using antibody microarray. PLoS One. 10 (4), e0125405 (2015).","journal-title":"PLoS One"},{"issue":"22","key":"81693_CR47","doi-asserted-by":"publisher","first-page":"15691","DOI":"10.1074\/jbc.M113.534206","volume":"289","author":"IK Hong","year":"2014","unstructured":"Hong, I. K. et al. The tetraspanin CD81 protein increases melanoma cell motility by up-regulating metalloproteinase MT1-MMP expression through the pro-oncogenic akt-dependent Sp1 activation signaling pathways. J. Biol. Chem. 289 (22), 15691\u201315704 (2014).","journal-title":"J. Biol. Chem."},{"issue":"38","key":"81693_CR48","doi-asserted-by":"publisher","first-page":"62377","DOI":"10.18632\/oncotarget.11481","volume":"7","author":"T Boyer","year":"2016","unstructured":"Boyer, T. et al. Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia. Oncotarget 7 (38), 62377\u201362385 (2016).","journal-title":"Oncotarget"},{"key":"81693_CR49","doi-asserted-by":"publisher","first-page":"106029","DOI":"10.1016\/j.biocel.2021.106029","volume":"137","author":"M Floren","year":"2021","unstructured":"Floren, M. & Gillette, J. M. Acute myeloid leukemia: therapy resistance and a potential role for tetraspanin membrane scaffolds. Int. J. Biochem. Cell. Biol. 137, 106029 (2021).","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"3","key":"81693_CR50","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/cyto.b.21533","volume":"94","author":"CC Cardoso","year":"2018","unstructured":"Cardoso, C. C. et al. The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry. Cytometry B Clin. Cytom. 94 (3), 451\u2013458 (2018).","journal-title":"Cytometry B Clin. Cytom"},{"issue":"5","key":"81693_CR51","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/00365513.2021.1929446","volume":"81","author":"A Espasa","year":"2021","unstructured":"Espasa, A. et al. Flow cytometric expression of CD71, CD81, CD44 and CD39 in B cell lymphoma. Scand. J. Clin. Lab. Invest. 81 (5), 413\u2013417 (2021).","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"2","key":"81693_CR52","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.humpath.2009.07.022","volume":"41","author":"RF Luo","year":"2010","unstructured":"Luo, R. F. et al. CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. Hum. Pathol. 41 (2), 271\u2013280 (2010).","journal-title":"Hum. Pathol."},{"issue":"4","key":"81693_CR53","doi-asserted-by":"publisher","first-page":"427","DOI":"10.15252\/embr.201439834","volume":"16","author":"AC Hedman","year":"2015","unstructured":"Hedman, A. C., Smith, J. M. & Sacks, D. B. The biology of IQGAP proteins: beyond the cytoskeleton. EMBO Rep. 16 (4), 427\u2013446 (2015).","journal-title":"EMBO Rep."},{"key":"81693_CR54","doi-asserted-by":"crossref","unstructured":"Song, F., Dai, Q., Grimm, M. O. & Steinbach, D. The antithetic roles of IQGAP2 and IQGAP3 in cancers. Cancers (Basel) ;15(4). (2023).","DOI":"10.3390\/cancers15041115"},{"issue":"1","key":"81693_CR55","first-page":"321","volume":"42","author":"H Su","year":"2019","unstructured":"Su, H., Chang, J., Xu, M., Sun, R. & Wang, J. CDK6 overexpression resulted from microRNA\u2013320d downregulation promotes cell proliferation in diffuse large B\u2013cell lymphoma. Oncol. Rep. 42 (1), 321\u2013327 (2019).","journal-title":"Oncol. Rep."},{"issue":"11","key":"81693_CR56","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1002\/ijc.33054","volume":"147","author":"S Nebenfuehr","year":"2020","unstructured":"Nebenfuehr, S., Kollmann, K. & Sexl, V. The role of CDK6 in cancer. Int. J. Cancer. 147 (11), 2988\u20132995 (2020).","journal-title":"Int. J. Cancer"},{"issue":"5","key":"81693_CR57","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.3390\/app12052268","volume":"12","author":"A Lo Giudice","year":"2022","unstructured":"Lo Giudice, A. et al. The clinical role of SRSF1 expression in Cancer: a review of the current literature. Appl. Sci. 12 (5), 2268 (2022).","journal-title":"Appl. Sci."},{"issue":"1","key":"81693_CR58","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41392-021-00495-6","volume":"6","author":"Y Lv","year":"2021","unstructured":"Lv, Y. et al. SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer. Signal. Transduct. Target. Ther. 6 (1), 108 (2021).","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"4","key":"81693_CR59","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cell.2010.07.019","volume":"142","author":"MJ Moore","year":"2010","unstructured":"Moore, M. J., Wang, Q., Kennedy, C. J. & Silver, P. A. An alternative splicing network links cell-cycle control to apoptosis. Cell 142 (4), 625\u2013636 (2010).","journal-title":"Cell"},{"issue":"3","key":"81693_CR60","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccr.2014.07.010","volume":"26","author":"Y Wang","year":"2014","unstructured":"Wang, Y. et al. The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression. Cancer Cell. 26 (3), 374\u2013389 (2014).","journal-title":"Cancer Cell."},{"issue":"8","key":"81693_CR61","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.7150\/jca.69274","volume":"13","author":"SP Salifu","year":"2022","unstructured":"Salifu, S. P. & Doughan, A. New clues to prognostic biomarkers of four hematological malignancies. J. Cancer. 13 (8), 2490\u20132503 (2022).","journal-title":"J. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81693-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81693-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81693-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T16:05:06Z","timestamp":1733155506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81693-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["81693"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81693-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BH holds shares in Novo Nordisk A\/S and Genmab A\/S. Novo Nordisk A\/S and Genmab A\/S had no influence on the study design, analyses and reporting of results. All other authors declare no relevant competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"29962"}}